Recent Company News

• 02:39 PM ET Oct 23, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 25-Oct

• 07:02 AM ET Oct 20, 2026
  

  NovaBridge majority-owned subsidiary Visara secures exclusive option for potential acquisition of YOL104-2 for ocular surface squamous neoplasia ($1.30, 0.00)

• 07:36 AM ET Oct 19, 2026
  

  Biogen to present new data across nephrology portfolio, including long-term EMPAVELI (pegcetacoplan) Phase 3 results, at American Society of Nephrology (ASN) Kidney Week ($232.65, 0.00)

• 03:04 PM ET Oct 16, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 18-Oct

• 07:07 AM ET Oct 13, 2026
  

  NovaBridge Biosciences subsidiary Visara expands ophthalmology pipeline with exclusive license for investigational nerve growth factor therapy for neurotrophic keratitis ($1.32, 0.00)

• 04:08 PM ET Oct 08, 2026
  

  NovaBridge Biosciences announces expanded Givastomig safety and efficacy data to be presented at ESMO 2026 ($1.37, 0.00)

• 10:08 AM ET Sep 25, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (154 total)

• 11:15 AM ET Sep 24, 2026
  

  StreetAccount Summary - US unusual volume traders

• 10:01 AM ET Sep 24, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (179 total)

• 10:16 AM ET Sep 14, 2026
  

  Transcript Intelligence: NovaBridge Biosciences at H.C. Wainwright Global Investment Conference ($1.62, +0.02)